metformin has been researched along with Cardiotoxicity in 20 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although several pharmacological interventions, including melatonin and metformin, have been reported to protect against various cardiovascular diseases, their potential roles in trastuzumab-induced cardiotoxicity remain elusive." | 8.31 | Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Nawara, W; Prathumsap, N; Shinlapawittayatorn, K, 2023) |
| "To explore whether metformin reduces cardiotoxicity of doxorubicin through the AMPK pathway." | 8.31 | [Metformin mitigates doxorubicin-induced cardiotoxicity ( Lin, L; Wei, J; Yang, Q; Zhu, C, 2023) |
| " The objective of the current study was to examine the protective role of metformin (MET) and/or low dose radiation (LDR) on cardiotoxicity and apoptosis induced by CP in rats." | 7.96 | Metformin and/or low dose radiation reduces cardiotoxicity and apoptosis induced by cyclophosphamide through SIRT-1/SOD and BAX/Bcl-2 pathways in rats. ( El Kiki, SM; Hasan, HF; Mansour, HH; Omran, MM, 2020) |
| "Carfilzomib (Cfz), an irreversible proteasome inhibitor licensed for relapsed/refractory myeloma, is associated with cardiotoxicity in humans." | 7.91 | Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. ( Agrogiannis, G; Andreadou, I; Davos, CH; Dimopoulos, MA; Efentakis, P; Iliodromitis, EK; Kanaki, Z; Kastritis, E; Klinakis, A; Konstantinidou, A; Kremastiotis, G; Nikolaou, PE; Papanagnou, ED; Terpos, E; Trougakos, IP; Tsoumani, M; Varela, A, 2019) |
| "The present study provided evidence that metformin has cardioprotective effects against doxorubicin cardiotoxicity." | 7.83 | Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. ( Argun, M; Baykan, A; Çilenk, KT; Derya, K; Elmalı, F; Narin, F; Narin, N; Özyurt, A; Pamukcu, Ö; Sönmez, MF; Unalmış, S; Üzüm, K, 2016) |
| " Unfortunately, cumulative and irreversible cardiotoxicity of Dox is the most prominent adverse effect which limits its use." | 5.62 | Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Ongnok, B; Prathumsap, N; Shinlapawittayatorn, K, 2021) |
| "The metformin-treated group received 250 mg/kg/day metformin via gavage." | 5.48 | The Cardioprotective Effect of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy. ( Czegledi, A; Czompa, A; Gajtko, A; Lekli, I; Pituk, D; Tosaki, A; Zilinyi, R, 2018) |
| " Although several pharmacological interventions, including melatonin and metformin, have been reported to protect against various cardiovascular diseases, their potential roles in trastuzumab-induced cardiotoxicity remain elusive." | 4.31 | Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Nawara, W; Prathumsap, N; Shinlapawittayatorn, K, 2023) |
| "To explore whether metformin reduces cardiotoxicity of doxorubicin through the AMPK pathway." | 4.31 | [Metformin mitigates doxorubicin-induced cardiotoxicity ( Lin, L; Wei, J; Yang, Q; Zhu, C, 2023) |
| " The objective of the current study was to examine the protective role of metformin (MET) and/or low dose radiation (LDR) on cardiotoxicity and apoptosis induced by CP in rats." | 3.96 | Metformin and/or low dose radiation reduces cardiotoxicity and apoptosis induced by cyclophosphamide through SIRT-1/SOD and BAX/Bcl-2 pathways in rats. ( El Kiki, SM; Hasan, HF; Mansour, HH; Omran, MM, 2020) |
| "Carfilzomib (Cfz), an irreversible proteasome inhibitor licensed for relapsed/refractory myeloma, is associated with cardiotoxicity in humans." | 3.91 | Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. ( Agrogiannis, G; Andreadou, I; Davos, CH; Dimopoulos, MA; Efentakis, P; Iliodromitis, EK; Kanaki, Z; Kastritis, E; Klinakis, A; Konstantinidou, A; Kremastiotis, G; Nikolaou, PE; Papanagnou, ED; Terpos, E; Trougakos, IP; Tsoumani, M; Varela, A, 2019) |
| "The present study provided evidence that metformin has cardioprotective effects against doxorubicin cardiotoxicity." | 3.83 | Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats. ( Argun, M; Baykan, A; Çilenk, KT; Derya, K; Elmalı, F; Narin, F; Narin, N; Özyurt, A; Pamukcu, Ö; Sönmez, MF; Unalmış, S; Üzüm, K, 2016) |
| " Unfortunately, cumulative and irreversible cardiotoxicity of Dox is the most prominent adverse effect which limits its use." | 1.62 | Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics. ( Arinno, A; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Kerdphoo, S; Khuanjing, T; Maneechote, C; Ongnok, B; Prathumsap, N; Shinlapawittayatorn, K, 2021) |
| "The metformin-treated group received 250 mg/kg/day metformin via gavage." | 1.48 | The Cardioprotective Effect of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy. ( Czegledi, A; Czompa, A; Gajtko, A; Lekli, I; Pituk, D; Tosaki, A; Zilinyi, R, 2018) |
| "Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion." | 1.43 | Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. ( Ekström, N; Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Miftaraj, M; Svensson, AM; Zethelius, B, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 12 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazo-Alvarez, JC | 1 |
| Pal, K | 1 |
| Pham, TM | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Sharma, M | 1 |
| Kuburas, R | 1 |
| Gharanei, M | 1 |
| Haussmann, I | 1 |
| Maddock, H | 1 |
| Sandhu, H | 1 |
| Nageeb, MM | 1 |
| Saadawy, SF | 1 |
| Attia, SH | 1 |
| Arinno, A | 3 |
| Maneechote, C | 3 |
| Khuanjing, T | 3 |
| Prathumsap, N | 3 |
| Chunchai, T | 3 |
| Arunsak, B | 3 |
| Nawara, W | 2 |
| Kerdphoo, S | 3 |
| Shinlapawittayatorn, K | 3 |
| Chattipakorn, SC | 4 |
| Chattipakorn, N | 4 |
| Alzokaky, AA | 1 |
| Al-Karmalawy, AA | 1 |
| Saleh, MA | 1 |
| Abdo, W | 1 |
| Farage, AE | 1 |
| Belal, A | 1 |
| Abourehab, MAS | 1 |
| Antar, SA | 1 |
| Satyam, SM | 1 |
| Bairy, LK | 1 |
| Shetty, P | 1 |
| Sainath, P | 1 |
| Bharati, S | 1 |
| Ahmed, AZ | 1 |
| Singh, VK | 1 |
| Ashwal, AJ | 1 |
| Yi, Y | 1 |
| Zhang, H | 1 |
| Chen, M | 1 |
| Chen, B | 1 |
| Chen, Y | 1 |
| Li, P | 1 |
| Zhou, H | 1 |
| Ma, Z | 1 |
| Jiang, H | 1 |
| Osataphan, N | 1 |
| Phrommintikul, A | 1 |
| Leemasawat, K | 1 |
| Somwangprasert, A | 1 |
| Apaijai, N | 1 |
| Suksai, S | 1 |
| Sirikul, W | 1 |
| Gunaparn, S | 1 |
| Wei, J | 2 |
| Yang, Q | 1 |
| Lin, L | 1 |
| Zhu, C | 1 |
| Timm, KN | 1 |
| Tyler, DJ | 1 |
| El Kiki, SM | 1 |
| Omran, MM | 1 |
| Mansour, HH | 1 |
| Hasan, HF | 1 |
| Ongnok, B | 1 |
| Zilinyi, R | 1 |
| Czompa, A | 1 |
| Czegledi, A | 1 |
| Gajtko, A | 1 |
| Pituk, D | 1 |
| Lekli, I | 1 |
| Tosaki, A | 1 |
| Scheen, AJ | 1 |
| Efentakis, P | 1 |
| Kremastiotis, G | 1 |
| Varela, A | 1 |
| Nikolaou, PE | 1 |
| Papanagnou, ED | 1 |
| Davos, CH | 1 |
| Tsoumani, M | 1 |
| Agrogiannis, G | 1 |
| Konstantinidou, A | 1 |
| Kastritis, E | 1 |
| Kanaki, Z | 1 |
| Iliodromitis, EK | 1 |
| Klinakis, A | 1 |
| Dimopoulos, MA | 1 |
| Trougakos, IP | 1 |
| Andreadou, I | 1 |
| Terpos, E | 1 |
| Moreb, JS | 1 |
| Kobashigawa, LC | 1 |
| Xu, YC | 1 |
| Padbury, JF | 1 |
| Tseng, YT | 2 |
| Yano, N | 1 |
| Argun, M | 1 |
| Üzüm, K | 1 |
| Sönmez, MF | 1 |
| Özyurt, A | 1 |
| Derya, K | 1 |
| Çilenk, KT | 1 |
| Unalmış, S | 1 |
| Pamukcu, Ö | 1 |
| Baykan, A | 1 |
| Narin, F | 1 |
| Elmalı, F | 1 |
| Narin, N | 1 |
| Ekström, N | 1 |
| Svensson, AM | 1 |
| Miftaraj, M | 1 |
| Franzén, S | 1 |
| Zethelius, B | 1 |
| Eliasson, B | 1 |
| Gudbjörnsdottir, S | 1 |
2 reviews available for metformin and Cardiotoxicity
| Article | Year |
|---|---|
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antibiotics, Antineoplastic; Cal | 2020 |
[Cardiovascular safety of DPP-4 inhibitors compared to that of sulfonylureas].
Topics: Cardiotoxicity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic | 2018 |
1 trial available for metformin and Cardiotoxicity
| Article | Year |
|---|---|
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Topics: Breast Neoplasms; Cardiotoxicity; Donepezil; Doxorubicin; Female; Humans; Leukocytes, Mononuclear; M | 2023 |
17 other studies available for metformin and Cardiotoxicity
| Article | Year |
|---|---|
Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice.
Topics: Adult; Aged; Body Mass Index; Cardiotoxicity; Cardiovascular Diseases; Comorbidity; Diabetes Mellitu | 2021 |
Metformin Protects Against Sunitinib-induced Cardiotoxicity: Investigating the Role of AMPK.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cardiotoxicity; | 2022 |
Breast milk mesenchymal stem cells abate cisplatin-induced cardiotoxicity in adult male albino rats via modulating the AMPK pathway.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Antioxidants; Apoptosis; bcl-2-Associated X | 2022 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy.
Topics: Animals; Cardiotoxicity; Inflammation; Male; Melatonin; Metformin; Mitochondria; Rats; Rats, Wistar; | 2023 |
Metformin ameliorates doxorubicin-induced cardiotoxicity targeting HMGB1/TLR4/NLRP3 signaling pathway in mice.
Topics: Animals; Cardiotoxicity; Caspase 3; Doxorubicin; HMGB1 Protein; Inflammasomes; Male; Metformin; Mice | 2023 |
Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach.
Topics: Animals; Antioxidants; Cardiotoxicity; Diabetes Mellitus, Type 2; Doxorubicin; Electrocardiography; | 2023 |
Inhibition of multiple uptake transporters in cardiomyocytes/mitochondria alleviates doxorubicin-induced cardiotoxicity.
Topics: Animals; Cardiotoxicity; Doxorubicin; Membrane Transport Proteins; Metformin; Mice; Mitochondria; My | 2023 |
[Metformin mitigates doxorubicin-induced cardiotoxicity
Topics: AMP-Activated Protein Kinases; Animals; Cardiotoxicity; Doxorubicin; Humans; Metformin; Mice; Mice, | 2023 |
Metformin and/or low dose radiation reduces cardiotoxicity and apoptosis induced by cyclophosphamide through SIRT-1/SOD and BAX/Bcl-2 pathways in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cardiotoxicity; Cyclophosphamide; Endothelin-1; Gamm | 2020 |
Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Cell Line; Dose-Response R | 2021 |
The Cardioprotective Effect of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy.
Topics: Animals; Autophagy; Biomarkers; Blood Pressure; Cardiac Output; Cardiotonic Agents; Cardiotoxicity; | 2018 |
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.
Topics: AMP-Activated Protein Kinases; Animals; Cardiotoxicity; Hypoglycemic Agents; Male; Metformin; Mice; | 2019 |
Off-target effects of carfilzomib that cause cardiotoxicity.
Topics: Animals; Cardiotoxicity; Metformin; Mice; Oligopeptides; Proteasome Inhibitors | 2019 |
Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Cycl | 2014 |
Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiotoxicity; Doxorubicin; Hypoglycemic Agents | 2016 |
Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Doxorubicin; Humans; Metformin; Oxidative Stress; Rats; | 2016 |
Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Topics: Aged; Blood Glucose; Cardiotoxicity; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, T | 2016 |